Sichuan Kelun-Biotech Secures IND Approval for Novel Dual-Payload ADC SKB565 from NMPA
Key Highlights
- Investigational New Drug (IND) approval received for SKB565, a novel dual-payload antibody drug conjugate (ADC), by the National Medical Products Administration (NMPA) of China.
- This marks Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.’s first dual-payload ADC entering the clinical stage for advanced solid tumor treatments.
- SKB565 is a core product from the company’s proprietary OptiDC™ platform, leveraging both toxin and immunomodulator payloads for a dual mechanism of action.
- The company is advancing an “ADC + immune-oncology (IO)” strategy, exploring high-value combination regimens in cancer therapeutics.
- Preclinical studies of SKB565 demonstrated excellent anti-tumor activity and safety, supporting further clinical development.
Detailed Overview
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKEX: 6990) announced a significant milestone with the approval by China’s NMPA for the clinical trial application of its innovative dual-payload ADC, SKB565. This IND approval allows the company to initiate clinical trials, targeting advanced solid tumors—a major step in bringing this next-generation oncology therapy to patients.
Strategic Pipeline and Technological Edge
The company has established a diversified pipeline of innovative molecules, focusing on high-value targets, differentiated designs, and global commercial potential. Leveraging its expertise in ADC technology, Sichuan Kelun-Biotech is also advancing an integrated “ADC + IO” strategy. This includes:
- Ongoing clinical studies combining ADCs with PD-(L)1 monoclonal antibodies.
- Development of SKB118, a PD-1/VEGF bispecific antibody, in combination with the company’s proprietary ADC portfolio.
- Innovative drug design strategies that incorporate synergistic functional components within a single ADC molecule.
About SKB565: A Next-Generation Dual-Payload ADC
SKB565 is developed using the company’s proprietary OptiDC™ platform and represents a new generation of ADCs capable of delivering both toxins and immunomodulators directly to tumor tissue. This dual-payload design enables:
- Targeted tumor cell killing through cytotoxic agents.
- Activation of the immune system within the tumor microenvironment, resulting in a stronger and more durable anti-tumor immune response.
In preclinical studies, SKB565 exhibited excellent anti-tumor activity and safety, highlighting its strong therapeutic potential and justifying its advancement to clinical trials.
Shareholder Considerations & Potential Impact
- Price Sensitivity: The IND approval for SKB565 is a potentially price-moving event, signaling progress in the company’s pipeline and potential future value creation if clinical results are positive.
- Risk Warning: It is important for shareholders and potential investors to note that SKB565 may not ultimately be successfully developed or commercialized. As with all early-stage drug candidates, there are significant development and regulatory risks.
- Investors should exercise caution and monitor upcoming clinical results and further pipeline updates as these may significantly influence the company’s valuation.
Management and Board
The company’s board is chaired by Mr. Liu Gexin, with a strong slate of executive and non-executive directors, including experienced leaders in science, medicine, and business.
Conclusion
The IND approval for SKB565 marks a significant advancement for Sichuan Kelun-Biotech in the highly competitive field of cancer therapeutics. With its innovative dual-payload ADC technology and integrated “ADC + IO” strategy, the company is well-positioned for future growth, although investors should remain mindful of the inherent risks in biopharmaceutical development.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisors before making investment decisions. The clinical and commercial outcomes for SKB565 remain uncertain.
四川科倫博泰生物製藥獲NMPA批准SKB565新藥臨床試驗申請
重點內容
- SKB565（雙重載體抗體藥物偶聯物）獲中國國家藥品監督管理局（NMPA）批准新藥臨床試驗（IND）申請。
- 這是四川科倫博泰首款雙重載體ADC進入臨床階段，目標治療晚期實體腫瘤。
- SKB565來自公司自有OptiDC™平台，結合毒素及免疫調節劑雙重機制。
- 公司積極推進“ADC + 免疫腫瘤學（IO）”策略，探索腫瘤治療多元組合。
- SKB565前期臨床前研究顯示其抗腫瘤活性及安全性優異，具進一步臨床開發潛力。
詳細報導
四川科倫博泰生物製藥有限公司（港交所：6990）公佈，SKB565新型雙重載體ADC藥物獲中國NMPA批准進行臨床試驗，標誌著公司在先進腫瘤治療領域的重要進展。此次IND獲批，將開啟SKB565用於晚期實體腫瘤的臨床研究，有望為未來腫瘤患者帶來新治療選擇。
技術及管線優勢
公司建立了多元化創新藥物管線，專注高價值靶點、差異化設計及全球化潛力。憑藉ADC技術優勢，正推進“ADC + IO”綜合策略，包括：
- ADC與PD-(L)1單抗的臨床組合研究。
- 開發PD-1/VEGF雙特異性抗體SKB118，並與自有ADC組合。
- 在單一ADC分子中整合協同功能成分的創新藥物設計。
SKB565產品詳情
SKB565基於OptiDC™平台開發，屬新一代雙重載體ADC，能將毒素及免疫調節劑直接送達腫瘤組織，具備兩大機制：
- 通過細胞毒素精準殺傷腫瘤細胞。
- 激活腫瘤微環境內免疫系統，產生更強及持久的抗腫瘤免疫反應。
臨床前研究顯示SKB565抗腫瘤活性及安全性突出，具臨床開發潛力。
股東須知及潛在影響
- 股價敏感性：SKB565獲IND批準屬重大利好，或對公司股價產生正面影響，反映公司管線進展及未來價值提升的潛力。
- 風險提示：SKB565能否最終成功開發及商業化存在重大不確定性，投資者須注意該項目仍屬初期階段，風險較高。
- 建議投資者持續關注臨床進展及後續公告，因相關結果或顯著影響公司估值。
管理層及董事會
公司由劉革新先生擔任董事會主席，團隊包含多名資深科學、醫藥及商業領袖。
總結
SKB565臨床試驗獲批，標誌著科倫博泰在腫瘤創新藥領域更進一步。公司憑藉雙重載體ADC創新技術及“ADC + IO”策略，具未來增長潛力，但投資者須留意相關藥物開發的不確定性與風險。
免責聲明
本文僅供資訊參考，並不構成任何投資建議。投資者應自行審慎評估並諮詢專業意見。SKB565最終能否成功開發及商業化仍存在不確定性。
